Key Sessions
Karen Pinachyan
What could we learn from commercialising a gene therapy in Europe for haemophilia B?
CSL Behring
Nasser Sadr
Beyond Empty vs Full: Understanding Heterogeneity in AAV Products and Impurities
uniQure
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference - Day 3 - GMT (Greenwich Mean Time, GMTZ)
keyboard_arrow_leftSearch & Filter
search
Streams
Clear
Main Conference - Day 3 - GMT (Greenwich Mean Time, GMTZ)
search
Streams
Clear
Showing 1 of 1 Streams
Cell Therapy Manufacturing & Analytics
11:15 - 11:20
Chairperson's Opening Remarks
- Alex Templar - Senior Business Development Manager - Manufacturing, Cell and Gene Therapy Catapult
11:20 - 11:55
Auto Cell Therapy & Vector Manufacturing Costs – Main Effects, Trends & Scales
- Rob Noel - Head of Consultancy, Biopharm Services Ltd
11:55 - 12:30
Accelerating in-house GMP Capabilities' through Collaboration
- Alex Templar - Senior Business Development Manager - Manufacturing, Cell and Gene Therapy Catapult
12:30 - 13:00
Why focusing on a quality end product from the beginning makes sense | Managing your journey to commercialization with quality raw materials.
Whilst advanced therapies (AT’s) are at the cutting edge of medicine, there is a disparity between these products and their raw materials. Serum-derived human and animal components are often utilized throughout the AT manufacturing process. Albumin is a natural multitool, its binding properties, tendency to act as an antioxidant, ability to reduce surface adsorption and mitigate aggregation make it useful across multiple unit applications. The variability in serum-derived albumins directly results from albumin's innate binding properties. This variability can directly impact your process and product. Join Dr Phil Morton, CTO of Albumedix, to discover how recombinant albumin could better support your AT’s process consistency.
- Phil Morton - Chief Technology Officer, Albumedix
Showing 1 of 1 Streams
Cell Therapy Manufacturing & Analytics
14:15 - 14:55
Process Analytical Technologies and Their Uses in Developing Closed, Automated and Adaptable Processes
- Jahid Hasan - Lead Technical Scientist, The Cell and Gene Therapy Catapult
Showing 1 of 1 Streams
Cell Therapy Manufacturing & Analytics
15:40 - 16:15
Academic Experience on Cell Therapy Cryopreservation and Freeze-Thawing and its Implications for Successful Treatment
- Guido Moll - Co-Principle Investigator & Deputy Group Leader, Charité Universitätsmedizin Berlin
16:15 - 16:20
End of Cell Therapy Manufacturing Track
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Clear